Share Price and Basic Stock Data
Last Updated: October 15, 2025, 3:28 pm
| PEG Ratio | -1.09 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Hemant Surgical Industries Ltd operates in the surgical instruments sector and reported a market capitalization of ₹323 Cr. The company’s sales figures have shown variability, with reported sales of ₹109 Cr in FY 2023, slightly declining to ₹106 Cr in FY 2024, and projected to recover to ₹107 Cr in FY 2025. Quarterly sales reflect this trend, with ₹58 Cr recorded in Mar 2023, and a slight decrease to ₹48 Cr in Sep 2023. Operating Profit Margin (OPM) stood at 10% for FY 2023 but saw fluctuations in quarterly performance, peaking at 13% in Mar 2024. The company’s revenue growth has been under pressure, particularly in the latter half of 2023, which may suggest challenges in maintaining consistent demand or pricing power within the sector. The surgical instruments industry is competitive, and Hemant Surgical’s ability to adapt to market dynamics will be crucial for its revenue trajectory moving forward.
Profitability and Efficiency Metrics
Hemant Surgical Industries reported a Net Profit of ₹8 Cr in FY 2023, with a significant increase to ₹10 Cr in FY 2024, reflecting a net profit margin of 9.27% that is commendable within the industry context. The earnings per share (EPS) were recorded at ₹9.95 in FY 2023, declining slightly to ₹9.39 in FY 2024. The company has maintained a robust Return on Equity (ROE) of 13.6% and Return on Capital Employed (ROCE) of 16.4%, indicating effective utilization of equity and capital for generating profits. The Interest Coverage Ratio (ICR) of 15.21x highlights the company’s strong ability to meet interest obligations, suggesting a low risk of financial distress. However, the decline in OPM to 9% in FY 2025 from a peak of 13% in Mar 2024 raises concerns about potential cost management issues or pricing pressures that could affect future profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Hemant Surgical Industries reflects a prudent financial management strategy, with total borrowings reported at ₹31 Cr against reserves of ₹53 Cr, resulting in a healthy Debt-to-Equity ratio of 0.12. This indicates a strong equity base relative to debt, reducing financial risk. The company’s current ratio of 1.83 and quick ratio of 1.28 suggest solid liquidity, providing a buffer against short-term financial obligations. Furthermore, the Price-to-Book Value (P/BV) ratio stands at 2.53x, which may indicate that the stock is trading at a premium compared to its book value, reflecting investor confidence in its long-term growth potential. However, the company must remain vigilant regarding its operational efficiency as indicated by the declining asset turnover ratio, which stood at 1.31% in Mar 2024, down from higher levels in previous years.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Hemant Surgical Industries indicates strong promoter confidence, with promoters holding 73.56% of the company as of Mar 2024. However, Foreign Institutional Investors (FIIs) have a minimal stake of 0.39%, while Domestic Institutional Investors (DIIs) hold 1.11% of the company. The public shareholding stood at 24.93%, indicating a diverse base of retail investors. The number of shareholders increased from 722 in Sep 2023 to 1,229 by Mar 2024, reflecting growing interest in the company. This increase in shareholder count may suggest that investor confidence is strengthening, despite the fluctuations in profitability and sales. The low FII participation could be a concern, as it may limit the stock’s liquidity and broader market appeal. The company’s ability to attract more institutional investors could enhance its credibility and valuation in the long term.
Outlook, Risks, and Final Insight
If margins sustain their levels and the company successfully navigates the competitive landscape, Hemant Surgical Industries could see a rebound in sales and profitability. The risks include potential fluctuations in raw material costs and pricing pressures, which could impact margins further. Additionally, the company’s reliance on a limited number of institutional investors raises concerns about market volatility. Strengths such as a strong promoter holding and a healthy balance sheet position the company well for future growth opportunities. If operational efficiency is improved and market conditions become favorable, Hemant Surgical could regain momentum in its revenue growth while maintaining profitability. The focus should be on improving operational margins and expanding market share to enhance overall investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Hemant Surgical Industries Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Hemant Surgical Industries Ltd | 316 Cr. | 303 | 367/88.2 | 39.5 | 60.3 | 0.00 % | 16.4 % | 13.6 % | 10.0 |
| Industry Average | 316.00 Cr | 303.00 | 39.50 | 60.30 | 0.00% | 16.40% | 13.60% | 10.00 |
Quarterly Result
| Metric | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Sales | 51 | 58 | 48 | 58 | 49 | 58 |
| Expenses | 47 | 52 | 44 | 51 | 45 | 52 |
| Operating Profit | 4 | 6 | 3 | 7 | 4 | 6 |
| OPM % | 8% | 11% | 7% | 13% | 7% | 10% |
| Other Income | 1 | 1 | 3 | 2 | 2 | 3 |
| Interest | 1 | 1 | 1 | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 4 | 6 | 5 | 8 | 4 | 6 |
| Tax % | 36% | 18% | 17% | 27% | 29% | 18% |
| Net Profit | 2 | 5 | 4 | 6 | 3 | 5 |
| EPS in Rs | 48.12 | 6.93 | 3.75 | 5.63 | 3.05 | 4.74 |
Last Updated: May 31, 2025, 8:57 am
Below is a detailed analysis of the quarterly data for Hemant Surgical Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 58.00 Cr.. The value appears strong and on an upward trend. It has increased from 49.00 Cr. (Sep 2024) to 58.00 Cr., marking an increase of 9.00 Cr..
- For Expenses, as of Mar 2025, the value is 52.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 45.00 Cr. (Sep 2024) to 52.00 Cr., marking an increase of 7.00 Cr..
- For Operating Profit, as of Mar 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Sep 2024) to 6.00 Cr., marking an increase of 2.00 Cr..
- For OPM %, as of Mar 2025, the value is 10.00%. The value appears strong and on an upward trend. It has increased from 7.00% (Sep 2024) to 10.00%, marking an increase of 3.00%.
- For Other Income, as of Mar 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Sep 2024) to 3.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 1.00 Cr..
- For Depreciation, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 1.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Sep 2024) to 6.00 Cr., marking an increase of 2.00 Cr..
- For Tax %, as of Mar 2025, the value is 18.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.00% (Sep 2024) to 18.00%, marking a decrease of 11.00%.
- For Net Profit, as of Mar 2025, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Sep 2024) to 5.00 Cr., marking an increase of 2.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is 4.74. The value appears strong and on an upward trend. It has increased from 3.05 (Sep 2024) to 4.74, marking an increase of 1.69.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 1:32 pm
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 56 | 56 | 60 | 101 | 109 | 106 | 107 |
| Expenses | 48 | 53 | 53 | 57 | 95 | 98 | 95 | 97 |
| Operating Profit | 2 | 3 | 3 | 3 | 6 | 11 | 10 | 9 |
| OPM % | 5% | 5% | 5% | 5% | 6% | 10% | 10% | 9% |
| Other Income | 0 | 0 | 0 | 1 | 2 | 2 | 4 | 5 |
| Interest | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 |
| Depreciation | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 1 | 1 | 1 | 6 | 10 | 13 | 11 |
| Tax % | 10% | 8% | 41% | 9% | 25% | 24% | 23% | 23% |
| Net Profit | 1 | 1 | 0 | 1 | 5 | 8 | 10 | 8 |
| EPS in Rs | 50.76 | 61.02 | 27.00 | 73.43 | 248.92 | 9.95 | 9.39 | 7.79 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -100.00% | 400.00% | 60.00% | 25.00% | -20.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -100.00% | 500.00% | -340.00% | -35.00% | -45.00% |
Hemant Surgical Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2018-2019 to 2024-2025.
Growth
Last Updated: September 5, 2025, 6:30 am
Balance Sheet
Last Updated: October 10, 2025, 2:12 pm
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 8 | 10 | 10 |
| Reserves | 5 | 6 | 5 | 8 | 11 | 16 | 44 | 53 |
| Borrowings | 9 | 11 | 14 | 14 | 10 | 7 | 7 | 31 |
| Other Liabilities | 12 | 14 | 23 | 15 | 32 | 34 | 38 | 54 |
| Total Liabilities | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 |
| Fixed Assets | 7 | 8 | 10 | 11 | 12 | 13 | 18 | 40 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 |
| Investments | 0 | 0 | 1 | 0 | 1 | 0 | 5 | 1 |
| Other Assets | 21 | 25 | 33 | 29 | 42 | 51 | 77 | 94 |
| Total Assets | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 |
Below is a detailed analysis of the balance sheet data for Hemant Surgical Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.00 Cr..
- For Reserves, as of Mar 2025, the value is 53.00 Cr.. The value appears strong and on an upward trend. It has increased from 44.00 Cr. (Mar 2024) to 53.00 Cr., marking an increase of 9.00 Cr..
- For Borrowings, as of Mar 2025, the value is 31.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 7.00 Cr. (Mar 2024) to 31.00 Cr., marking an increase of 24.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 54.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 38.00 Cr. (Mar 2024) to 54.00 Cr., marking an increase of 16.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 148.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 100.00 Cr. (Mar 2024) to 148.00 Cr., marking an increase of 48.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 40.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Mar 2024) to 40.00 Cr., marking an increase of 22.00 Cr..
- For CWIP, as of Mar 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 12.00 Cr., marking an increase of 12.00 Cr..
- For Investments, as of Mar 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.00 Cr. (Mar 2024) to 1.00 Cr., marking a decrease of 4.00 Cr..
- For Other Assets, as of Mar 2025, the value is 94.00 Cr.. The value appears strong and on an upward trend. It has increased from 77.00 Cr. (Mar 2024) to 94.00 Cr., marking an increase of 17.00 Cr..
- For Total Assets, as of Mar 2025, the value is 148.00 Cr.. The value appears strong and on an upward trend. It has increased from 100.00 Cr. (Mar 2024) to 148.00 Cr., marking an increase of 48.00 Cr..
Notably, the Reserves (53.00 Cr.) exceed the Borrowings (31.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -7.00 | -8.00 | -11.00 | -11.00 | -4.00 | 4.00 | 3.00 | -22.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 36 | 35 | 26 | 56 | 58 | 75 | 70 |
| Inventory Days | 64 | 73 | 125 | 113 | 57 | 67 | 99 | 205 |
| Days Payable | 102 | 97 | 143 | 89 | 92 | 110 | 116 | 188 |
| Cash Conversion Cycle | -3 | 12 | 17 | 51 | 21 | 15 | 58 | 87 |
| Working Capital Days | 12 | 23 | -28 | 41 | -19 | 2 | 52 | 61 |
| ROCE % | 15% | 12% | 14% | 32% | 45% | 30% | 16% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | 7.70 |
| Diluted EPS (Rs.) | 7.70 |
| Cash EPS (Rs.) | 9.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 60.51 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 60.51 |
| Revenue From Operations / Share (Rs.) | 102.14 |
| PBDIT / Share (Rs.) | 13.50 |
| PBIT / Share (Rs.) | 12.14 |
| PBT / Share (Rs.) | 10.02 |
| Net Profit / Share (Rs.) | 7.70 |
| NP After MI And SOA / Share (Rs.) | 7.70 |
| PBDIT Margin (%) | 13.21 |
| PBIT Margin (%) | 11.88 |
| PBT Margin (%) | 9.81 |
| Net Profit Margin (%) | 7.54 |
| NP After MI And SOA Margin (%) | 7.54 |
| Return on Networth / Equity (%) | 12.72 |
| Return on Capital Employeed (%) | 14.55 |
| Return On Assets (%) | 5.42 |
| Long Term Debt / Equity (X) | 0.36 |
| Total Debt / Equity (X) | 0.49 |
| Current Ratio (X) | 1.45 |
| Quick Ratio (X) | 0.74 |
| Interest Coverage Ratio (X) | 6.40 |
| Interest Coverage Ratio (Post Tax) (X) | 4.65 |
| Enterprise Value (Cr.) | 125.52 |
| EV / Net Operating Revenue (X) | 1.18 |
| EV / EBITDA (X) | 8.90 |
| MarketCap / Net Operating Revenue (X) | 0.97 |
| Price / BV (X) | 1.65 |
| Price / Net Operating Revenue (X) | 0.97 |
| EarningsYield | 0.07 |
After reviewing the key financial ratios for Hemant Surgical Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.07. This value is within the healthy range. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.51. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.51. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 102.14. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.50. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.14. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.02. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 25, the value is 13.21. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 25, the value is 11.88. This value is within the healthy range. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 25, the value is 9.81. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 25, the value is 7.54. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.54. This value is below the healthy minimum of 8. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.72. This value is below the healthy minimum of 15. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.55. This value is within the healthy range. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 25, the value is 5.42. This value is within the healthy range. No previous period data is available for comparison.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.36. This value is within the healthy range. No previous period data is available for comparison.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.49. This value is within the healthy range. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 6.40. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.65. This value is within the healthy range. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 25, the value is 125.52. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.18. This value is within the healthy range. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 25, the value is 8.90. This value is within the healthy range. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 25, the value is 1.65. This value is within the healthy range. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hemant Surgical Industries Ltd:
- Net Profit Margin: 7.54%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.55% (Industry Average ROCE: 16.4%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.72% (Industry Average ROE: 13.6%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.65
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.74
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 39.5 (Industry average Stock P/E: 39.5)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.49
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.54%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | 502, 5th Floor, Ecstasy Business Park Co-Op Socteiy Limited, Mumbai Maharashtra 400080 | info@hemantsurgical.com http://www.hemantsurgical.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Hanskumar Shah | Chairman & Managing Director |
| Mr. Kaushik Hanskumar Shah | WholeTime Director & CFO |
| Mr. Hemant Praful Shah | Whole Time Director |
| Mrs. Nehal Babu Karelia | Non Executive Director |
| Mr. Ketan Chandrakat Dave | Independent Director |
| Mrs. Kshama Dharnidharka | Independent Director |
FAQ
What is the intrinsic value of Hemant Surgical Industries Ltd?
Hemant Surgical Industries Ltd's intrinsic value (as of 15 October 2025) is 264.33 which is 12.76% lower the current market price of 303.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 316 Cr. market cap, FY2025-2026 high/low of 367/88.2, reserves of ₹53 Cr, and liabilities of 148 Cr.
What is the Market Cap of Hemant Surgical Industries Ltd?
The Market Cap of Hemant Surgical Industries Ltd is 316 Cr..
What is the current Stock Price of Hemant Surgical Industries Ltd as on 15 October 2025?
The current stock price of Hemant Surgical Industries Ltd as on 15 October 2025 is 303.
What is the High / Low of Hemant Surgical Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Hemant Surgical Industries Ltd stocks is 367/88.2.
What is the Stock P/E of Hemant Surgical Industries Ltd?
The Stock P/E of Hemant Surgical Industries Ltd is 39.5.
What is the Book Value of Hemant Surgical Industries Ltd?
The Book Value of Hemant Surgical Industries Ltd is 60.3.
What is the Dividend Yield of Hemant Surgical Industries Ltd?
The Dividend Yield of Hemant Surgical Industries Ltd is 0.00 %.
What is the ROCE of Hemant Surgical Industries Ltd?
The ROCE of Hemant Surgical Industries Ltd is 16.4 %.
What is the ROE of Hemant Surgical Industries Ltd?
The ROE of Hemant Surgical Industries Ltd is 13.6 %.
What is the Face Value of Hemant Surgical Industries Ltd?
The Face Value of Hemant Surgical Industries Ltd is 10.0.